Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy

le
0
Strasbourg, France, May 31, 2016, 6:00 pm CET – Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today announced that a poster on the ongoing Pexa-Vec Phase 3 trial in first line advanced HCC patients will be presented at the American Society of Clinical Oncology (ASCO) Meeting on June 4th, in Chicago, IL, USA.

Date and Time: Saturday, June 4, 2016, 8:00 a.m. – 11:30 a.m. CDT
Abstract Title: PHOCUS: A Phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by Sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.
Abstract Number: TPS4146
Location: Hall A
Poster Board: #130b
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Presenter: Ghassan K. Abou-Alfa, MD - Memorial Sloan Kettering Cancer Center
NCT02562755

The abstract is available via the following link: http://abstract.asco.org/176/AbstView_176_164722.html

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.


Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant